Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Pawel Gunerka (Lomianki, Poland), Pawel Gunerka, Joanna Hucz-Kalitowska, Pawel Turowski, Marcin Zagozda, Maciej Dziachan, Mariola Sekular, Anna Bujak, Maciej Wieczorek. Pharmacokinetics of selective PI3Kδ inhibitors after intratracheal instillation in mice. Eur Respir J 2015; 46: Suppl. 59, 2123

Member's Comments

No comment yet.

Related content which might interest you: Effect of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of AZD5069, an oral CXCR2 antagonist Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Effect of the combination of doxofylline and montelukast on LPS-induced leukocyte migration to the lung Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 The novel elastase inhibitor BAY 85-8501: Bioavailability and Food effect study to evaluate pharmacokinetics of tablet formulations Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Safety, tolerability and pharmacokinetics of a new inhaled once-daily phosphodiesterase (PDE) 4 inhibitor in healthy volunteers Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 In vivo efficacy of CHF6001, an inhaled PDE4 inhibitor with a wide therapeutic window Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 CHI-91040, a novel inhaled p38α inhibitor, counteracts lung inflammation induced by IL-1β in the rat Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Laninamivir’s prolonged intrapulmonary retention: Intrapulmonary pharmacokinetics (PK) and the intracellular disposition to support the long-lasting efficacy after an inhaled administration of its prodrug laninamivir octanoate (LO) Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013 Comparing the effects of orally and intranasally administered IKK2 inhibitors in a 4 day tobacco-smoke exposed model of COPD Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways Year: 2013 Effects of intratracheal pf-00610355, an inhaled β2 adrenoceptor agonist, in anaesthetised animals Source: Annual Congress 2009 - New bronchodilators Year: 2009 Pharmacokinetics and local tolerance of an IL-4/IL-13 antagonist inhalation powder in humans Source: Annual Congress 2008 - New mechanisms in the pathogenesis of asthma and its response to treatment Year: 2008 A combination of thyme and ivy exerts potent anti-inflammatory and mucus-normalizing activity in vivo and inhibits 5-LO and PDE4 Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Bronchoprotective activity and safety assessment of two novel dual-acting MABA compounds (LAS190792 and LAS191351) in dogs Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 In vitro profile of the new inhaled pan-JAK inhibitor LAS194046 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Pharmacokinetics of PF-00610355, a novel inhaled long-acting β2-adrenoreceptor agonist Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 The effects of intra-nasally administered anti-inflammatory compounds in a mouse model of acute COPD exacerbations Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 The novel elastase inhibitor BAY 85-8501: First-in-man study to evaluate safety, tolerability and pharmacokinetics in healthy male subjects Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Pharmacological characterization of CHI25243, a novel potent inhaled inhibitor of neutrophil elastase Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models Year: 2016 Therapeutic potential of CPL-407-105 – Novel potent JAK/STAT pathway inhibitor for the treatment of asthma Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Inhibition of matrix metalloproteinase-2 activity by propranolol in immunocompetent cells Source: Annual Congress 2013 –Studies of asthma in man Year: 2013